Nonetheless, it seems that MMDs are generally preferred to measure the efficacy of anti-CGRP MAbs in line with established guidelines [80], although there is no evidence to clearly demonstrate the superiority of this metric over MHDs due to a lack of consensus concerning the definition of a migraine day [81]. This evidence concerns the gene CALCA and migraine disorder.